These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 344110)

  • 1. Clinical immunotherapy experiences in the Southeastern Cancer Study Group.
    Gordon DS
    Dev Biol Stand; 1977 Apr 13-15; 38():567-72. PubMed ID: 344110
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of immunotherapy in acute myelogenous leukemia.
    Foon KA; Smalley RV; Riggs CW; Gale RP
    Arch Intern Med; 1983 Sep; 143(9):1726-31. PubMed ID: 6577818
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bacillus Calmette-Guérin immunotherapy in combination with DTIC (NSC-45388) for the treatment of malignant melanoma.
    Gutterman JU; Mavligit GM; Reed R; Burgess MA; Gottlieb J; Hersh EM
    Cancer Treat Rep; 1976 Feb; 60(2):177-82. PubMed ID: 769970
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemoimmunotherapy for disseminated malignant melanoma: a prospective randomized study.
    Ramseur WL; Richards F; Muss HB; Rhyne L; Cooper MR; White DR; Stuart JJ; Spurr CL
    Cancer Treat Rep; 1978 Jul; 62(7):1085-7. PubMed ID: 356970
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Experience with BCG adjuvant immunotherapy in stage II malignant melanoma.
    Peter HH; Deutschmann EM; Schultheis W; Deicher H
    Dev Biol Stand; 1977 Apr 13-15; 38():537-40. PubMed ID: 344106
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy in malignant melanomaa.
    Homes EC; Morton DL; Eilber FR; Golub SE; Sulit HL
    Natl Cancer Inst Monogr; 1976 Nov; 44():85-6. PubMed ID: 799763
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapy in the management of myelogenous leukemia.
    Fairley GH
    Arch Intern Med; 1976 Dec; 136(12):1406-12. PubMed ID: 793553
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemoimmunotherapy (DTIC and Corynebacterium parvum) as adjuvant treatment in malignant melanoma.
    Karakousis CP; Didolkar MS; Lopez R; Baffi R; Moore R; Holyoke ED
    Cancer Treat Rep; 1979; 63(11-12):1739-43. PubMed ID: 393377
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intralesional BCG application in malignant melanoma.
    Sopková B; Kolár V
    Neoplasma; 1976; 23(4):421-6. PubMed ID: 794745
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized controlled trial of adjuvant chemoimmunotherapy with DTIC and BCG after complete excision of primary melanoma with a poor prognosis or melanoma metastases.
    Can Med Assoc J; 1983 Apr; 128(8):929-33. PubMed ID: 6339024
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BCG and cancer.
    Bast RC; Zbar B; Borsos T; Rapp HJ
    N Engl J Med; 1974 Jun; 290(26):1458-69. PubMed ID: 4598691
    [No Abstract]   [Full Text] [Related]  

  • 12. Ineffectiveness of adjuvant chemotherapy using DTIC and cyclophosphamide in patients with resectable metastatic melanoma.
    Balch CM; Murray D; Presant C; Bartolucci AA
    Surgery; 1984 Apr; 95(4):454-9. PubMed ID: 6369594
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Immunotherapy of acute myelogenous leukemia (AML) in adults with the Nocardia rubra cell wall skeleton].
    Ohno R; Nakamura H; Kodera Y; Masaoka T; Yamada K
    Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 2):1264-9. PubMed ID: 3524463
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Surgical treatment of malignant melanoma.
    Rosenberg SA
    Cancer Treat Rep; 1976 Feb; 60(2):159-63. PubMed ID: 769968
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapy of melanoma with intralesional BCG.
    Bornstein RS; Mastrangelo MJ; Sulit H; Chee D; Yarbro JW; Prehn LM; Prehn RT
    Natl Cancer Inst Monogr; 1973 Dec; 39():213-20. PubMed ID: 4595320
    [No Abstract]   [Full Text] [Related]  

  • 16. Adjuvant BCG immunotherapy for stage I and II malignant melanoma.
    Silver HK; Ibrahim EM; Evers JA; Thomas JW; Murray RN; Spinelli JJ
    Can Med Assoc J; 1983 Jun; 128(11):1291-5. PubMed ID: 6342739
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapy in acute leukemias. Possible applications in children.
    Mahoney DH; Starling KA
    Am J Pediatr Hematol Oncol; 1981; 3(4):410-8. PubMed ID: 7036781
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy for chronic myelogenous leukemia: survival not affected by treatment in the stable phase.
    Baker MA; Taub RN; Carter WH; Davidson M; Sutton DM; Kutas G; Berger S; Watt HJ
    Cancer Res; 1984 Jan; 44(1):383-5. PubMed ID: 6360347
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I/II SECSG (Southeastern Cancer Study Group) pilot study of surgical adjuvant immunotherapy with vaccinia melanoma oncolysates (VMO).
    Wallack MK; McNally K; Michaelides M; Bash J; Bartolucci A; Siegler H; Balch C; Wanebo H
    Am Surg; 1986 Mar; 52(3):148-51. PubMed ID: 3513682
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic factors in metastatic melanoma patients treated with biochemotherapy and maintenance immunotherapy.
    Minor DR; Moore D; Kim C; Kashani-Sabet M; Venna SS; Wang W; Boasberg P; O'Day S
    Oncologist; 2009 Oct; 14(10):995-1002. PubMed ID: 19776094
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.